

EVIDENCE MAP OF PRO INSTRUMENTS USED IN STUDIES OF PROSTATE CANCER SINCE 1960

Alex Furber¹, Alison Martin¹, Cassandra Springate¹

¹ Crystallise Ltd alex.furber@crystallise.com

Objectives:

- To create an Evidence Map of patient-reported outcome (PRO) studies of patients with prostate cancer, the geographical settings in which these studies were conducted, and the interventions assessed.

Methods:

- The **heoro.com** database indexes publications available on PubMed according to study types, diseases, interventions and locations.
- We identified all PRO studies of prostate cancer published between 1960 and 5th March 2018 in the heoro.com database and indexed these by intervention, location, population, study methodology, disease stage and PRO tool used.

Results:

- We identified **763** independent publications

Table 1: Number of abstracts by year reporting specific population types

	Caregiver	General population	HCP	Patient
1960:1989	0	0	0	2
1990:1994	1	1	2	12
1995:1999	1	5	4	97
2000:2004	5	8	6	220
2005:2009	1	6	0	130
2010:2014	1	7	4	169
2015:2018	1	2	0	104

Figure 1: Number of publications by geographical region




Table 2: Top 15 reported PRO tools

AUA-SI	18
EORTC QLQ-C30	101
EORTC QLQ-PR25	47
EPIC	87
EQ-5D	31
FACT-G	27
FACT-P	49
IIEF-5	27
IPSS	35
RTOG-EORTC-SS	17
SF-12	21
SF-36	120
TTO	16
UCLA-PCI	93
VAS	21


Table 3: Reported interventions by disease stage

	Advanced	Any or unknown	At risk	End of life	Local	Metastatic	Recurrent	Refractory	Survivors
Abiraterone	0	0	0	0	0	3	0	1	0
Bisphosphonate	0	1	0	0	0	8	0	1	0
Brachytherapy	4	26	0	0	55	3	1	0	1
Chemotherapy	7	6	0	0	0	22	0	2	0
Gefitinib	1	1	0	0	0	0	0	0	0
HIFU	0	0	0	0	4	0	2	0	0
Hormonal	36	48	0	0	23	30	1	3	2
None	9	67	3	6	12	12	0	0	15
PDEi	0	2	0	0	1	1	0	0	0
Palliative care	2	0	0	0	0	1	0	0	0
Psychological	1	7	0	0	3	2	0	0	2
Radiotherapy	22	79	0	0	107	11	4	0	4
Screening	0	1	27	0	0	0	0	0	0
Surgery	17	110	0	0	117	12	4	0	2
Surveillance	3	7	0	0	28	3	0	0	1
Taxane	2	2	0	0	0	10	0	0	0
Unclear	3	20	1	0	11	5	0	0	3
Various	5	49	5	0	13	7	1	0	7

Table 4: Reported study methodologies

	Count
Case study	1
Case-control	16
Clinical trial	244
Cohort	160
Cross-sectional	166
Economic model	9
Mapping to utility	10
Narrative review	6
Protocol	14
Systematic review	35
Validation	118

FIGURE 2: Abstracts by publication year



Conclusions:

- We identified 182 PRO tools used in studies of prostate cancer. Of these, 19 were specific to prostate cancer only. The most commonly-cited tool was the SF-36 (120 abstracts) with the US (335) or UK (74) the most common locations and surgery (251) or radiotherapy (216) as the main intervention.
- PRO tools measured complications (145 abstracts), symptoms (119), treatment (74), comorbidities (37), utility (200), social impact (5), patient knowledge (12), satisfaction (21), views (18), disease (298) or were non-specific (256).

Download the free Evidence Map:



Crystallise Ltd, Unit 21 Thames Enterprise Centre, Thames Industrial Park, East Tilbury, Essex UK RM18 8RH Tel: +44 01375 488020

For a copy of this poster or the Evidence Map, email: alison.martin@crystallise.com

www.crystallise.com www.heoro.com

Presented at ISOQOL 25th Annual Conference
Dublin, Ireland. October 24th to 27th 2018.